| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cloud Computing | 5 | 2024 | 14 | 2.480 |
Why?
|
| Spinal Cord Injuries | 9 | 2023 | 109 | 2.360 |
Why?
|
| Genomics | 13 | 2024 | 848 | 2.070 |
Why?
|
| Neoplasms | 20 | 2025 | 3169 | 2.010 |
Why?
|
| Software | 10 | 2023 | 670 | 1.980 |
Why?
|
| Databases, Factual | 9 | 2025 | 1006 | 1.780 |
Why?
|
| Biomedical Research | 9 | 2024 | 438 | 1.620 |
Why?
|
| Information Dissemination | 7 | 2024 | 124 | 1.570 |
Why?
|
| Genome, Human | 8 | 2021 | 823 | 1.410 |
Why?
|
| Neuroprotective Agents | 2 | 2023 | 98 | 1.410 |
Why?
|
| Electronic Health Records | 3 | 2024 | 372 | 1.300 |
Why?
|
| Cervical Cord | 2 | 2023 | 15 | 1.000 |
Why?
|
| Datasets as Topic | 3 | 2017 | 81 | 0.920 |
Why?
|
| Riluzole | 2 | 2023 | 15 | 0.900 |
Why?
|
| Veterans | 2 | 2024 | 99 | 0.900 |
Why?
|
| Databases, Genetic | 3 | 2021 | 282 | 0.880 |
Why?
|
| Precision Medicine | 10 | 2025 | 456 | 0.850 |
Why?
|
| Neck Injuries | 1 | 2023 | 14 | 0.800 |
Why?
|
| Vocabulary, Controlled | 1 | 2023 | 11 | 0.780 |
Why?
|
| National Cancer Institute (U.S.) | 6 | 2024 | 72 | 0.780 |
Why?
|
| Genome, Bacterial | 3 | 2022 | 142 | 0.770 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1660 | 0.770 |
Why?
|
| Computational Biology | 6 | 2019 | 578 | 0.760 |
Why?
|
| Data Accuracy | 2 | 2022 | 32 | 0.750 |
Why?
|
| Medical Informatics | 2 | 2024 | 48 | 0.750 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 152 | 0.730 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2022 | 12 | 0.720 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 109 | 0.710 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 61 | 0.710 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 52 | 0.700 |
Why?
|
| Liquid Biopsy | 6 | 2025 | 48 | 0.700 |
Why?
|
| Medical Oncology | 4 | 2024 | 404 | 0.690 |
Why?
|
| Humans | 74 | 2025 | 93511 | 0.680 |
Why?
|
| Drosophila melanogaster | 6 | 2014 | 630 | 0.640 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 208 | 0.600 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 543 | 0.590 |
Why?
|
| Disease | 2 | 2017 | 92 | 0.590 |
Why?
|
| Gene Regulatory Networks | 3 | 2010 | 317 | 0.570 |
Why?
|
| Mutation | 6 | 2024 | 4272 | 0.550 |
Why?
|
| Spatial Analysis | 1 | 2017 | 11 | 0.530 |
Why?
|
| Information Storage and Retrieval | 4 | 2023 | 126 | 0.530 |
Why?
|
| Schools, Medical | 3 | 2024 | 131 | 0.520 |
Why?
|
| Algorithms | 6 | 2023 | 1953 | 0.520 |
Why?
|
| Data Collection | 1 | 2018 | 370 | 0.510 |
Why?
|
| Neuroblastoma | 2 | 2019 | 396 | 0.510 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 1762 | 0.480 |
Why?
|
| United States | 15 | 2024 | 7619 | 0.430 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 751 | 0.420 |
Why?
|
| Computer Systems | 1 | 2014 | 64 | 0.410 |
Why?
|
| Health Priorities | 3 | 2023 | 26 | 0.410 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2016 | 65 | 0.410 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 878 | 0.400 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1775 | 0.380 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1985 | 0.380 |
Why?
|
| Data Mining | 2 | 2014 | 44 | 0.370 |
Why?
|
| DNA Methylation | 4 | 2021 | 697 | 0.360 |
Why?
|
| Systems Biology | 1 | 2012 | 47 | 0.350 |
Why?
|
| Databases, Nucleic Acid | 1 | 2011 | 44 | 0.330 |
Why?
|
| Molecular Sequence Annotation | 3 | 2021 | 78 | 0.330 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2025 | 1261 | 0.330 |
Why?
|
| Models, Statistical | 3 | 2018 | 585 | 0.330 |
Why?
|
| Transcription Factors | 7 | 2014 | 1691 | 0.320 |
Why?
|
| Phenotype | 5 | 2022 | 2544 | 0.320 |
Why?
|
| Spinal Cord Diseases | 3 | 2021 | 88 | 0.320 |
Why?
|
| User-Computer Interface | 3 | 2021 | 189 | 0.300 |
Why?
|
| Models, Molecular | 2 | 2004 | 1353 | 0.290 |
Why?
|
| Base Sequence | 5 | 2021 | 2220 | 0.290 |
Why?
|
| Models, Biological | 2 | 2021 | 1768 | 0.290 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 2715 | 0.280 |
Why?
|
| Genome, Insect | 3 | 2014 | 78 | 0.260 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2007 | 9 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 893 | 0.250 |
Why?
|
| Computer Security | 3 | 2019 | 17 | 0.250 |
Why?
|
| Male | 18 | 2025 | 44553 | 0.240 |
Why?
|
| Computer Graphics | 1 | 2006 | 100 | 0.240 |
Why?
|
| Genome | 1 | 2009 | 407 | 0.240 |
Why?
|
| Diagnostic Imaging | 2 | 2025 | 452 | 0.240 |
Why?
|
| Multiple Sclerosis | 4 | 2002 | 261 | 0.240 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 220 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 2 | 2007 | 239 | 0.230 |
Why?
|
| Health Information Interoperability | 1 | 2025 | 7 | 0.230 |
Why?
|
| Data Curation | 1 | 2025 | 10 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 306 | 0.220 |
Why?
|
| Specimen Handling | 2 | 2025 | 109 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2465 | 0.210 |
Why?
|
| Computer Communication Networks | 2 | 2016 | 24 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 269 | 0.210 |
Why?
|
| Chemistry | 1 | 2004 | 49 | 0.210 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 985 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2004 | 37 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2023 | 342 | 0.200 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2014 | 166 | 0.200 |
Why?
|
| Copper | 1 | 2023 | 79 | 0.200 |
Why?
|
| Decompression, Surgical | 2 | 2023 | 157 | 0.190 |
Why?
|
| Halomonadaceae | 2 | 2013 | 4 | 0.190 |
Why?
|
| Chromatin | 5 | 2014 | 440 | 0.190 |
Why?
|
| Brain | 6 | 2016 | 2391 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2004 | 218 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2003 | 3476 | 0.190 |
Why?
|
| Internet | 3 | 2017 | 337 | 0.190 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 135 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 139 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 76 | 0.180 |
Why?
|
| Female | 19 | 2025 | 48698 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 146 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 97 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 117 | 0.170 |
Why?
|
| Half-Life | 1 | 2021 | 93 | 0.170 |
Why?
|
| Prognosis | 4 | 2023 | 3910 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 1 | 2023 | 449 | 0.170 |
Why?
|
| 5-Methylcytosine | 2 | 2019 | 121 | 0.170 |
Why?
|
| Disease Progression | 1 | 2025 | 1531 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 148 | 0.160 |
Why?
|
| Viruses | 1 | 2021 | 64 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 962 | 0.160 |
Why?
|
| Chromothripsis | 1 | 2020 | 9 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 620 | 0.160 |
Why?
|
| Academic Success | 1 | 2020 | 11 | 0.160 |
Why?
|
| Curriculum | 1 | 2024 | 594 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 192 | 0.150 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 813 | 0.150 |
Why?
|
| Veterans Health | 1 | 2019 | 19 | 0.150 |
Why?
|
| Transcriptome | 1 | 2025 | 762 | 0.150 |
Why?
|
| Oncogenes | 1 | 2020 | 100 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2022 | 219 | 0.150 |
Why?
|
| Mutagenesis | 1 | 2020 | 192 | 0.150 |
Why?
|
| Telomerase | 1 | 2020 | 67 | 0.150 |
Why?
|
| Machine Learning | 4 | 2025 | 341 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 2365 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2020 | 106 | 0.150 |
Why?
|
| Telomere | 1 | 2020 | 120 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 372 | 0.150 |
Why?
|
| Epigenomics | 1 | 2019 | 109 | 0.150 |
Why?
|
| Ecosystem | 2 | 2023 | 396 | 0.140 |
Why?
|
| Students, Medical | 2 | 2024 | 435 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 391 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1053 | 0.140 |
Why?
|
| Access to Information | 1 | 2018 | 29 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2020 | 157 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 83 | 0.140 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 95 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 482 | 0.140 |
Why?
|
| Mexican Americans | 1 | 2017 | 70 | 0.130 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 630 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1914 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2022 | 3054 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1729 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 351 | 0.130 |
Why?
|
| Pets | 1 | 2017 | 10 | 0.130 |
Why?
|
| Models, Genetic | 2 | 2013 | 970 | 0.130 |
Why?
|
| Middle Aged | 9 | 2023 | 27569 | 0.130 |
Why?
|
| Research | 1 | 2018 | 251 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 381 | 0.120 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 107 | 0.120 |
Why?
|
| Computing Methodologies | 1 | 2016 | 8 | 0.120 |
Why?
|
| Time Factors | 2 | 2024 | 5410 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 873 | 0.120 |
Why?
|
| Hemiptera | 2 | 2013 | 7 | 0.120 |
Why?
|
| Phylogeny | 1 | 2022 | 1266 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 537 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 580 | 0.120 |
Why?
|
| Dogs | 1 | 2017 | 634 | 0.120 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 76 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 266 | 0.120 |
Why?
|
| Computer Simulation | 3 | 2025 | 1118 | 0.110 |
Why?
|
| White Matter | 1 | 2016 | 96 | 0.110 |
Why?
|
| DNA, Bacterial | 2 | 2013 | 232 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10164 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1780 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1133 | 0.110 |
Why?
|
| Symbiosis | 2 | 2013 | 128 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2023 | 9098 | 0.110 |
Why?
|
| Gene Expression | 1 | 2018 | 1301 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2018 | 1415 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 190 | 0.100 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2011 | 79 | 0.100 |
Why?
|
| Erythroid Cells | 1 | 2013 | 16 | 0.100 |
Why?
|
| Systems Integration | 1 | 2014 | 33 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1741 | 0.100 |
Why?
|
| Erythropoiesis | 1 | 2013 | 53 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 297 | 0.100 |
Why?
|
| Binding Sites | 3 | 2014 | 1133 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2013 | 120 | 0.100 |
Why?
|
| Metagenomics | 1 | 2014 | 100 | 0.100 |
Why?
|
| Animals | 11 | 2024 | 28155 | 0.100 |
Why?
|
| Incidence | 1 | 2017 | 1701 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 2 | 2024 | 7 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 80 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 4560 | 0.090 |
Why?
|
| Models, Chemical | 2 | 2004 | 185 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 1117 | 0.090 |
Why?
|
| Aged | 5 | 2022 | 20430 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 214 | 0.090 |
Why?
|
| Biotechnology | 1 | 2012 | 30 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 626 | 0.090 |
Why?
|
| Child | 5 | 2019 | 7355 | 0.090 |
Why?
|
| Uncertainty | 2 | 2023 | 78 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 240 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1338 | 0.090 |
Why?
|
| Gene Components | 1 | 2011 | 6 | 0.090 |
Why?
|
| North America | 2 | 2023 | 195 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 123 | 0.080 |
Why?
|
| Forecasting | 1 | 2012 | 293 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1518 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2011 | 209 | 0.080 |
Why?
|
| Research Design | 1 | 2014 | 617 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2495 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2017 | 2026 | 0.080 |
Why?
|
| Adult | 10 | 2020 | 27918 | 0.080 |
Why?
|
| Radiology | 1 | 2012 | 192 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1225 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2012 | 443 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2802 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 556 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 306 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 740 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2010 | 521 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2020 | 171 | 0.070 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 228 | 0.070 |
Why?
|
| Blood Volume | 1 | 2007 | 42 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3110 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2303 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 179 | 0.060 |
Why?
|
| Registries | 2 | 2023 | 990 | 0.060 |
Why?
|
| Spinal Cord | 2 | 1998 | 241 | 0.060 |
Why?
|
| Spinal Canal | 1 | 1986 | 6 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 413 | 0.060 |
Why?
|
| Facial Injuries | 1 | 1985 | 25 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2003 | 295 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 217 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1234 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 1985 | 58 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 884 | 0.060 |
Why?
|
| Bangladesh | 1 | 2025 | 339 | 0.050 |
Why?
|
| Program Development | 1 | 2024 | 131 | 0.050 |
Why?
|
| Filtration | 1 | 2023 | 27 | 0.050 |
Why?
|
| Genotype | 2 | 2018 | 1866 | 0.050 |
Why?
|
| Reflex | 1 | 2023 | 80 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2003 | 8 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 98 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2003 | 66 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2024 | 238 | 0.050 |
Why?
|
| Database Management Systems | 1 | 2003 | 44 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2023 | 229 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 2479 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1931 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 264 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2024 | 179 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 484 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 234 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2020 | 66 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 59 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2020 | 43 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2003 | 299 | 0.040 |
Why?
|
| Sensation | 1 | 2020 | 48 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 9606 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2014 | 295 | 0.040 |
Why?
|
| College Admission Test | 1 | 2020 | 2 | 0.040 |
Why?
|
| Histones | 2 | 2013 | 361 | 0.040 |
Why?
|
| Suppositories | 1 | 2019 | 4 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2019 | 12 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 69 | 0.040 |
Why?
|
| Hypotension | 2 | 2019 | 72 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2019 | 20 | 0.040 |
Why?
|
| Skin Ulcer | 1 | 2019 | 27 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2020 | 29 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 2019 | 40 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 34 | 0.040 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 29 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 368 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 140 | 0.040 |
Why?
|
| Protein Binding | 2 | 2014 | 1534 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2024 | 822 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 1077 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 608 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 3220 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 2910 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 452 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2019 | 150 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1103 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 353 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2019 | 3829 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 6930 | 0.030 |
Why?
|
| Pneumonia | 1 | 2019 | 193 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 696 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 153 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 920 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 98 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 120 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 917 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1366 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 6 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 235 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 423 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 38 | 0.030 |
Why?
|
| Government Regulation | 1 | 2016 | 49 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 75 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 295 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2017 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 828 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 961 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 155 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 700 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1061 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 219 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 544 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 756 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 255 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 159 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 456 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7061 | 0.030 |
Why?
|
| Hematoma | 2 | 1985 | 106 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 554 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2014 | 49 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2016 | 322 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1847 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2013 | 47 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 775 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 48 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2013 | 82 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 161 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 391 | 0.020 |
Why?
|
| Inpatients | 1 | 1996 | 345 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 13 | 0.020 |
Why?
|
| Cytosine | 1 | 2013 | 121 | 0.020 |
Why?
|
| U937 Cells | 1 | 2012 | 31 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 48 | 0.020 |
Why?
|
| Publishing | 1 | 2014 | 91 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2013 | 174 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 69 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 216 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 271 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 248 | 0.020 |
Why?
|
| Risk Factors | 1 | 2022 | 5898 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 2 | 1985 | 367 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 379 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 517 | 0.020 |
Why?
|
| Insulator Elements | 1 | 2011 | 7 | 0.020 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2011 | 7 | 0.020 |
Why?
|
| Histone Code | 1 | 2011 | 19 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 784 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 526 | 0.020 |
Why?
|
| RNA, Small Untranslated | 1 | 2010 | 15 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 887 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 298 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 841 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2010 | 61 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 86 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2010 | 184 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1906 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2850 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2121 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1922 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2755 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 555 | 0.020 |
Why?
|
| Birth Injuries | 1 | 1985 | 3 | 0.010 |
Why?
|
| Orbital Fractures | 1 | 1985 | 13 | 0.010 |
Why?
|
| Mastoid | 1 | 1985 | 16 | 0.010 |
Why?
|
| Skull Fractures | 1 | 1985 | 26 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2484 | 0.010 |
Why?
|
| Brain Edema | 1 | 1985 | 58 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1985 | 153 | 0.010 |
Why?
|
| Brain Concussion | 1 | 1985 | 86 | 0.010 |
Why?
|
| Choline | 1 | 2003 | 24 | 0.010 |
Why?
|
| Creatine | 1 | 2003 | 27 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 228 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 12269 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1985 | 2585 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 165 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 262 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1998 | 225 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1996 | 87 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1977 | 194 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 140 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1996 | 172 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 988 | 0.010 |
Why?
|
| Cognition | 1 | 1998 | 627 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1977 | 578 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1910 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 77 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1977 | 344 | 0.000 |
Why?
|
| Hypertension | 1 | 1977 | 757 | 0.000 |
Why?
|